Robert Driscoll
Stock Analyst at Wedbush
(1.94)
# 2,972
Out of 4,732 analysts
155
Total ratings
30.28%
Success rate
-5.74%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Driscoll
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IDYA IDEAYA Biosciences | Reiterates: Outperform | $52 | $22.18 | +134.45% | 9 | Dec 17, 2024 | |
| RVMD Revolution Medicines | Maintains: Outperform | $70 → $67 | $40.29 | +66.29% | 4 | Dec 6, 2024 | |
| TYRA Tyra Biosciences | Reiterates: Outperform | $28 | $16.19 | +72.95% | 8 | Oct 25, 2024 | |
| BDTX Black Diamond Therapeutics | Reiterates: Outperform | $16 | $2.20 | +627.27% | 10 | Oct 8, 2024 | |
| RCUS Arcus Biosciences | Reiterates: Outperform | $30 | $14.03 | +113.83% | 7 | Oct 3, 2024 | |
| IGMS IGM Biosciences | Maintains: Outperform | $25 → $22 | $1.77 | +1,142.94% | 10 | Oct 1, 2024 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Outperform | $85 → $51 | $11.92 | +327.85% | 1 | Sep 20, 2024 | |
| ACET Adicet Bio | Reiterates: Outperform | $5 | $0.91 | +450.42% | 8 | Sep 20, 2024 | |
| CGEM Cullinan Therapeutics | Reiterates: Outperform | $36 | $10.26 | +250.88% | 4 | Sep 18, 2024 | |
| GLUE Monte Rosa Therapeutics | Reiterates: Outperform | $11 | $5.66 | +94.52% | 3 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $3.85 | +185.81% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $4 | $2.24 | +78.57% | 9 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $37 | $7.26 | +409.64% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $4.31 | +201.62% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $2.85 | +356.14% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $40.72 | +81.73% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $0.55 | +2,085.79% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $2.60 | +207.69% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $18.05 | +215.79% | 8 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $7 | $2.89 | +142.21% | 8 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3 → $8 | $0.84 | +852.38% | 9 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $0.71 | +1,024.70% | 7 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $52 | $10.14 | +412.82% | 5 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $39 → $35 | $12.54 | +179.11% | 5 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $1.33 | +576.69% | 1 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2 → $4 | $3.20 | +25.00% | 4 | May 19, 2020 |
IDEAYA Biosciences
Dec 17, 2024
Reiterates: Outperform
Price Target: $52
Current: $22.18
Upside: +134.45%
Revolution Medicines
Dec 6, 2024
Maintains: Outperform
Price Target: $70 → $67
Current: $40.29
Upside: +66.29%
Tyra Biosciences
Oct 25, 2024
Reiterates: Outperform
Price Target: $28
Current: $16.19
Upside: +72.95%
Black Diamond Therapeutics
Oct 8, 2024
Reiterates: Outperform
Price Target: $16
Current: $2.20
Upside: +627.27%
Arcus Biosciences
Oct 3, 2024
Reiterates: Outperform
Price Target: $30
Current: $14.03
Upside: +113.83%
IGM Biosciences
Oct 1, 2024
Maintains: Outperform
Price Target: $25 → $22
Current: $1.77
Upside: +1,142.94%
Corbus Pharmaceuticals Holdings
Sep 20, 2024
Maintains: Outperform
Price Target: $85 → $51
Current: $11.92
Upside: +327.85%
Adicet Bio
Sep 20, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.91
Upside: +450.42%
Cullinan Therapeutics
Sep 18, 2024
Reiterates: Outperform
Price Target: $36
Current: $10.26
Upside: +250.88%
Monte Rosa Therapeutics
Sep 12, 2024
Reiterates: Outperform
Price Target: $11
Current: $5.66
Upside: +94.52%
Aug 13, 2024
Reiterates: Outperform
Price Target: $11
Current: $3.85
Upside: +185.81%
Aug 12, 2024
Upgrades: Neutral
Price Target: $4
Current: $2.24
Upside: +78.57%
Aug 9, 2024
Reiterates: Outperform
Price Target: $37
Current: $7.26
Upside: +409.64%
Aug 9, 2024
Reiterates: Outperform
Price Target: $13
Current: $4.31
Upside: +201.62%
Aug 8, 2024
Maintains: Outperform
Price Target: $11 → $13
Current: $2.85
Upside: +356.14%
Aug 8, 2024
Reiterates: Outperform
Price Target: $74
Current: $40.72
Upside: +81.73%
Aug 7, 2024
Reiterates: Outperform
Price Target: $12
Current: $0.55
Upside: +2,085.79%
Aug 7, 2024
Reiterates: Outperform
Price Target: $8
Current: $2.60
Upside: +207.69%
Jul 31, 2024
Reiterates: Outperform
Price Target: $57
Current: $18.05
Upside: +215.79%
Jun 7, 2024
Reiterates: Outperform
Price Target: $7
Current: $2.89
Upside: +142.21%
May 9, 2024
Upgrades: Outperform
Price Target: $3 → $8
Current: $0.84
Upside: +852.38%
May 3, 2024
Reiterates: Outperform
Price Target: $8
Current: $0.71
Upside: +1,024.70%
Nov 8, 2023
Reiterates: Outperform
Price Target: $52
Current: $10.14
Upside: +412.82%
Nov 7, 2023
Maintains: Outperform
Price Target: $39 → $35
Current: $12.54
Upside: +179.11%
Aug 24, 2023
Initiates: Outperform
Price Target: $9
Current: $1.33
Upside: +576.69%
May 19, 2020
Upgrades: Outperform
Price Target: $2 → $4
Current: $3.20
Upside: +25.00%